The Company has been initially launched as a wholly-owned subsidiary of Evestra, Inc., a U.S.A. company based in San Antonio, Texas. The key mission of Evestra Onkologia is to engage in highly innovative Research and Development as it pertains to the development and commercialization of oncology and endometriosis assets in Poland, and beyond within the EU. In order to accomplish the core mission, the Company will establish a variety of fruitful collaborations with leading Polish research institutions and investigators in the oncology and gynecology area, as well as for-profit CRO companies in Poland, to enhance development and commercialization of its innovative assets. Evestra Onkologia’s managing board is led by two executives of the pharmaceutical industry whose extensive experience includes multinational pharmaceutical companies.
The two board members, Dr. Ze’ev Shaked, Ph.D and Dr. Klaus Nickisch, Ph.D have track records that include the development and commercialization of novel antimetabolites to treat hematological cancers, as well as biologics such as monoclonal antibodies and cytokines for the treatment a wide range of solid tumor indications. Both board members hold numerous patents and have managed R&D projects for many years.